Ionis Reaches Phase 3 Enrollment Milestone for Obudanersen
CARLSBAD, Calif., July 6, 2026 Ionis Pharmaceuticals announced the completion of enrollment for the pivotal pediatric cohort of its...
RNA therapy
Advertisement
Ionis Wins FDA Approval for TRYNGOLZA in Severe Hypertriglyceridemia
CARLSBAD, Calif., June 24, 2026 Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA®...
CureDuchenne and Tevard Biosciences Advance DMD Therapy
NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...
Twist Bioscience Unveils Plasmid Preps to Fuel Nucleic-Acid Therapeutics Research
San Francisco, CA – December 4, 2025 — Twist Bioscience today announced the launch of a new line of...
FDA Approves First RNA Therapy for Hereditary Angioedema Prophylaxis
CARLSBAD, Calif., August 21, 2025 — The U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen), the first...
Advertisement
